MedPath

Russian National Registry of LAAO

Completed
Conditions
Atrial Fibrillation
Registration Number
NCT04322474
Lead Sponsor
National Research Center for Preventive Medicine
Brief Summary

The first Russian registry presents data from two hundred consecutive patients with nonvalvular atrial fibrillation, who undergone left atrial appendage occlusion (LAAO) using the Watchman device and the Amplatzer cardiac plug. This government-funded catheter-based LAAO program was started in September 2015 and was completed in December 2017. Data collection was finished in December 2018. Five clinics agreed to participate in the study.

Patients' baseline characteristics, procedure, and follow up data were collected according to established registry protocol. Patients were followed at 45 days, 3, 6 and 12 months after enrollment. At each follow-up visit, the data regarding clinical events and healthcare utilization was collected.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
200
Inclusion Criteria
  • age ≥18 years nonvalvular atrial fibrillation,
  • CHA2DS2VASc ≥2,
  • high risk of hemorrhagic events,
  • non-compliance with pharmacological anticoagulant therapy
Exclusion Criteria
  • significant mitral valve disease,
  • left ventricular ejection fraction <35%,
  • the tendency to systemic thrombosis,
  • severe co-morbidities

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Procedure-related major adverse events (pericardial effusion, cardiac tamponade, device embolization, procedure/device-related death)12 months
The composite of thromboembolic events, device thrombosis, hemorrhagic events, unexplained death12 months

Primary efficacy endpoint

Secondary Outcome Measures
NameTimeMethod
Peridevice leakage6 months

incidence rates of significant (≥5mm) leakage

Procedure success rateintraprocedural

successful left atrial appendage occluder implantation rate

© Copyright 2025. All Rights Reserved by MedPath